Novartis has provided this community update on the status of the VIBRANT-HD trial, which will test branaplam, an oral huntingtin-lowering drug, in people with HD.
Novartis has provided this community update on the status of the VIBRANT-HD trial, which will test branaplam, an oral huntingtin-lowering drug, in people with HD.
